Viewing Study NCT00411905

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 3:33 AM
Ignite Modification Date: 2026-03-06 @ 1:33 AM
Study NCT ID: NCT00411905
Status: COMPLETED
Last Update Posted: 2025-01-07
First Post: 2006-12-14
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes
Sponsor: Groupe Francophone des Myelodysplasies
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Myelodysplastic Syndromes View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Myelodysplastic syndromes View
None IPSS Int-2 and High risk View
None Bortezomib View
None Low dose Cytarabine View
None Bone Marrow diseases View